CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02025985
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:50.005051+00:00
Published At: 2021-02-02T00:00:00+00:00
Record Updated At: 2023-01-26
Results Posted At: 2021-02-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Carcinoma", "Endometrial Carcinoma", "Cervical Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-01-26"
protocolSection.identificationModule.nctId: "NCT02025985"
protocolSection.identificationModule.officialTitle: "A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE\u2122 Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-02-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.